RECCE® 529
Viral infections
PreclinicalActive
Key Facts
About Recce Pharmaceuticals
Recce creates synthetic polymer anti‑infectives to combat multidrug‑resistant bacteria and viruses.
View full company profileTherapeutic Areas
Other Viral infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Haptenized Viral Vaccines | BioVaxys | Preclinical |
| Cell-based Antiviral Drug Discovery Platform | Lucerna | Development |
| XAV19 | Xenothera | Preclinical |
| Antiviral Screening Services | NeoVirTech | Pre-clinical |
| Anti-Viral Program | MicroQuin | Pre-clinical |
| Satiasolv | Marinomed Biotech | Pre-clinical |
| Telomir-1 | Telomir Pharmaceuticals | Pre-clinical |
| DehydraTECH for Antivirals | Lexaria Bioscience | Preclinical |